Key result
Following VATS pericardiectomy, patients with nonmalignant pericardial effusions had a significantly longer median survival time (5360 days) compared to those with malignant effusions (160 days, p=0.0015).
Why the study?
Does VATS pericardiectomy improve survival and performance status in patients with recurrent or symptomatic pericardial effusion?
Observational (n=29)
No
Does VATS pericardiectomy improve survival and performance status in patients with recurrent or symptomatic pericardial effusion?
Absolute Event Rate: 5360% vs 160%
p-value: p=0.0015
VATS pericardiectomy is an effective procedure that provides excellent long-term survival for benign pericardial effusions and improves performance status in malignant cases despite poor overall prognosis.
Survival disparity by etiology informs post-VATS prognosis; leaves open whether pericardiectomy improves outcomes versus alternatives.
PURPOSE: Chronic or recurrent pericardial effusion is often associated with malignant disease. However, there have been few reports of the long-term outcomes after video-assisted thoracoscopic (VATS) pericardiectomy. We have performed it since 1992, and report our procedure and outcomes. METHODS: Patients who underwent VATS pericardiectomy were investigated. RESULTS: In all, 29 patients (12 men; median age: 61 (23-88) years) were evaluated; 8 had no malignancies and 21 did. Preoperative performance status (PS) scores were as follows: 1, 11 patients; 2, 10 patients; 3, 5 patients; and 4, 2 patients. One patient with malignancy died intraoperatively. PS improved significantly after the procedure (p = 0.0163). Median survival times were 5360 days in the nonmalignant group, 160 days in the malignant group, 209 days in breast cancer patients, and 62 days in other malignancy patients. The nonmalignant group had significantly longer survival than the malignant group (p = 0.0015). Most cases had uneventful postoperative courses. No recurrent pericardial effusions have been observed. CONCLUSION: In cases of nonmalignant pericardial effusion, long-term survival is expected following VATS pericardiectomy. Malignant pericardial effusion has a poor prognosis, but most cases maintain good PS. However, early postoperative death may occur, and it is important to select patients carefully.
No takes yet. Share an insight, caveat, or question.
Mizukami et al. (2017) conducted an observational in Chronic or recurrent pericardial effusion (n=29). Video-assisted thoracoscopic (VATS) pericardiectomy vs. Malignant pericardial effusion (within-cohort comparison) was evaluated on Median survival time (nonmalignant vs malignant etiology) (p=0.0015). Following VATS pericardiectomy, patients with nonmalignant pericardial effusions had a significantly longer median survival time (5360 days) compared to those with malignant effusions (160 days, p=0.0015).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: